New pill shows promise in slowing rare Cancer's growth
NCT ID NCT07032285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targets enzymes involved in cell division and is still under investigation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Oncology Department, HU Fundación Jimenez Diaz
RECRUITINGMadrid, Madrid, 28040, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted procedure ease the burden of desmoid tumors?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can a Patient's own immune cells fight advanced sarcoma?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Could a genetic marker guide future cancer therapies in taiwan?
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors